Midatech Pharma (NASDAQ:MTP) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a report released on Thursday.
Shares of NASDAQ MTP traded up $0.07 during trading hours on Thursday, reaching $0.49. The stock had a trading volume of 257,800 shares, compared to its average volume of 107,026. The stock has a market cap of $12.74 million, a PE ratio of -0.67 and a beta of 1.35. Midatech Pharma has a fifty-two week low of $0.39 and a fifty-two week high of $2.65.
Midatech Pharma Company Profile
Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom. The company operates through two segments, Pipeline Research and Development; and Commercial. Its products include Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; Gelclair, an oral gel barrier device indicated for the management and relief of pain due to oral mucositis; Oravig, an orally dissolving buccal tablet for oral thrush; and Soltamox, an oral liquid solution of tamoxifen citrate, for the treatment and prevention of breast cancer.
Further Reading: How to Track your Portfolio in Google Finance
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.